stats
globeinteractive.com: Making the Business of Life Easier

   Finance globeinvestor   Careers globecareers.workopolis Subscribe to The Globe
The Globe and Mail /globeandmail.com
Home | Business | National | Int'l | Sports | Columnists | The Arts | Tech | Travel | TV | Wheels
space


Search

space
  This site         Tips

  
space
  The Web Google
space
   space



space

  Where to Find It


Breaking News
  Home Page

  Report on Business

  Sports

  Technology

space
Subscribe to The Globe

Shop at our Globe Store


Print Edition
  Front Page

  Report on Business

  National

  International

  Sports

  Arts & Entertainment

  Editorials

  Columnists

   Headline Index

 Other Sections
  Appointments

  Births & Deaths

  Books

  Classifieds

  Comment

  Education

  Environment

  Facts & Arguments

  Focus

  Health

  Obituaries

  Real Estate

  Review

  Science

  Style

  Technology

  Travel

  Wheels

 Leisure
  Cartoon

  Crosswords

  Food & Dining

  Golf

  Horoscopes

  Movies

  Online Personals

  TV Listings/News

 Specials & Series
  All Reports...

space

Services
   Where to Find It
 A quick guide to what's available on the site

 Newspaper
  Advertise

  Corrections

  Customer Service

  Help & Contact Us

  Reprints

  Subscriptions

 Web Site
  Advertise

  E-Mail Newsletters

  Free Headlines

  Globe Store New

  Help & Contact Us

  Make Us Home

  Mobile New

  Press Room

  Privacy Policy

  Terms & Conditions


GiveLife.ca

    

PRINT EDITION
Apotex in hot water with U.K. health officials
space
Pharma giant loses Indian manufacturing certificate on allegations of poor practices
space
By PAUL WALDIE
  
  

Email this article Print this article

space  Advertisement
space

Tuesday, January 9, 2018 – Page B2

LONDON -- Apotex Inc. has run into trouble with British health regulators who have pulled the manufacturing certificate from the Toronto-based company's sprawling operation in India and restricted the importation of drugs made there.

Britain's Medicines and Healthcare products Regulatory Agency (MHRA) pulled the certificate last month after officials inspected the plant in Bangalore, which is operated by an Apotex subsidiary called Apotex Research Pvt. Ltd. In a report on its November inspection, the MHRA said the plant "does not comply with the Good Manufacturing Practices requirements" and it cited several failings related to non-sterile products, packaging and quality-control testing.

The report also warned other European Union countries to "contact the site to determine the level of risk associated with specific products released to market." And it added that "no batches [are] to be supplied to EU markets whilst this statement of non-compliance remains in force with the exception of products agreed in writing between [Apotex] and individual competent authorities based on continuity of product supply being critical for continued patient treatment."

The regulatory action comes at a time of turmoil at the generic drug maker. Company founder, Barry Sherman, 75, and his wife, Honey, 70, were found dead at their Toronto home last month and police are still investigating what happened. Mr.

Sherman played a critical role at Apotex up until his death. Although he had stepped down as chief executive officer several years ago, he remained chairman and was still the company's chief formulation officer, designing virtually every dose formulation. It's unclear how his role will be replaced or what financial impact his death will have since the company is privately held.

The MHRA carries out regular inspections of plants that produce medical products licenced for the British market. A Good Manufacturing Practices certificate is the minimum standard that a drug maker must meet in their production process. "Factories will be inspected when you apply for a manufacturer or wholesaler dealer licence and then periodically based on risk assessments," an MHRA official said in an e-mailed statement.

"Overseas manufacturing sites are also inspected." The official added that "critical findings from MHRA inspections are infrequent."

Jordan Berman, an Apotex spokesman, said the company is working to resolve the MHRA's issues. "Apotex is taking a number of steps to address MHRA feedback including quarantining all EU destined products manufactured at [Apotex Research] that have not yet been released to market, and initiating risk assessments," he said in an e-mail.

All regulatory "agencies whose markets are supplied with finished products from [Apotex Research] have been contacted and advised of this development. Non-essential medicines are being held pending outcome of MHRA discussion."

He added that "manufacturing and release of products for non-EU markets will continue, and data driven risk assessments have been performed that show all of our products meet required release specifications where a perceived potential risk was emphasized."

India has been a growing part of Apotex's worldwide operations and last July it opened a 42,000-square-foot "global business services office" in Mumbai.

The Bangalore plant has been operating since 2004 and it now has more than 2,500 employees who develop and manufacture products for the United States, Canada, the EU and Australia.

This isn't the first time the Indian operation has run into problems with regulators. The U.S. Food and Drug Administration raised a number of serious concerns about the plant in 2014 and 2015, including a failure to keep proper laboratory and computer records; and improper quality-control measures. The company responded to the concerns and in December, 2016, the FDA acknowledged that the violations had been addressed.

Associated Graphic

Empty pill bottles are filled at the Apotex plant in Toronto in 2011. A British regulator determined the firm did 'not comply with the Good Manufacturing Practices requirements' in an Indian plant.

NORM BETTS/BLOOMBERG


Huh? How did I get here?
Return to Main Leah_McLaren Page
Subscribe to
The Globe and Mail
 

Email this article Print this article

space  Advertisement
space

Need CPR for your RSP? Check your portfolio’s pulse and lower yours by improving the overall health of your investments. Click here.

Advertisement

7-Day Site Search
    

Breaking News



Today's Weather


Inside

Rick Salutin
Merrily marching
off to war
Roy MacGregor
Duct tape might hold
when panic strikes


Editorial
Where Manley is going with his first budget




space

Columnists



For a columnist's most recent stories, click on their name below.

 National


Roy MacGregor arrow
This Country
space
Jeffrey Simpson arrow
The Nation
space
Margaret Wente arrow
Counterpoint
space
Hugh Winsor  arrow
The Power Game
space
 Business


Rob Carrick arrow
Personal Finance
space
Drew Fagan arrow
The Big Picture
space
Mathew Ingram arrow
space
Brent Jang arrow
Business West
space
Brian Milner arrow
Taking Stock
space
Eric Reguly arrow
To The Point
space
Andrew Willis arrow
Streetwise
space
 Sports


Stephen Brunt arrow
The Game
space
Eric Duhatschek arrow
space
Allan Maki arrow
space
William Houston arrow
Truth & Rumours
space
Lorne Rubenstein arrow
Golf
space
 The Arts


John Doyle arrow
Television
space
John MacLachlan Gray arrow
Gray's Anatomy
space
David Macfarlane arrow
Cheap Seats
space
Johanna Schneller arrow
Moviegoer
space
 Comment


Murray Campbell arrow
Ontario Politics
space
Lysiane Gagnon arrow
Inside Quebec
space
Marcus Gee arrow
The World
space
William Johnson arrow
Pit Bill
space
Paul Knox arrow
Worldbeat
space
Heather Mallick arrow
As If
space
Leah McLaren arrow
Generation Why
space
Rex Murphy arrow
Japes of Wrath
space
Rick Salutin arrow
On The Other Hand
space
Paul Sullivan arrow
The West
space
William Thorsell arrow
space





Home | Business | National | Int'l | Sports | Columnists | The Arts | Tech | Travel | TV | Wheels
space

© 2003 Bell Globemedia Interactive Inc. All Rights Reserved.
Help & Contact Us | Back to the top of this page